FDA advisory committees have supported the expanded use of CAR-T therapies, including those from Bristol Myers Squibb and Johnson & Johnson, for blood cancer treatment despite safety concerns. The FDA flagged risks of early death from adverse events but acknowledged the benefits of these therapies in treating multiple myeloma and chronic lymphocytic leukemia.
FDA panel backs broader use of J&J, Bristol Myers cell therapies for myeloma https://t.co/ZDx2xCjHAM $JNJ $BMY @ByJonGardner
A FDA panel voted in favor of expanding use of CAR-T therapy in multiple myeloma, despite concerns about side effects. https://t.co/s8XYCfPiHW
the legendary Breyanzi CVR Bristol Myers Squibb cell therapy gets FDA green light to treat common type of leukemia $BMY https://t.co/hDt1Gyey43
An FDA advisory committee has backed Carvykti and Abecma for use in earlier lines of treatment, but the real takeaway from the meeting is that it's time to prioritize rapid CAR T manufacturing https://t.co/h4zm8WXNSJ
US FDA panel votes in favor of expanded use of Bristol Myers' CAR-T therapy https://t.co/TN4OrUBSl9 https://t.co/OAhuFyMX8f
FDA panel backs broader use of J&J, Bristol Myers cell therapies for myeloma https://t.co/egWxVZ0DTc @ByJonGardner $JNJ $BMY $LEGN
An FDA advisory committee voted on Friday that the benefits of two CAR-T therapies, Carvykti and Abecma, outweigh their risks in earlier-stage multiple myeloma patients. Carvykti: 11-0 Abecma: 8-3 https://t.co/yWpiwAtvBY
A panel of expert advisers to the FDA voted in favor of expanding the use of CAR-T therapy in blood cancer, despite concerns about side effects. https://t.co/6DiMJn2Pm5
FDA advisers back CAR-T therapies in blood cancer, despite safety concerns https://t.co/MMQM0u1WZ2 via @statnews
FDA advisers back CAR-T therapies in blood cancer, despite safety concerns https://t.co/I78tsGAf0m
FDA advisers back CAR-T therapies in blood cancer, despite safety concerns https://t.co/YtalZLGDij via @damiangarde $JNJ $LEGN $BMY $TSVT
An FDA advisory committee voted unanimously on Friday that the benefits of Johnson & Johnson and Legend Biotech’s CAR-T therapy Carvykti outweigh its risks in earlier-stage multiple myeloma patients. https://t.co/Wen7V7W0kN
Despite early death concerns, FDA advisers back J&J and Legend's Carvykti for earlier myeloma https://t.co/ZDET1nhTsW
Bristol Myers nabs new FDA nod as Breyanzi brings CAR-T class to chronic lymphocytic leukemia https://t.co/UiZ8saZMpg
US FDA panel unanimously backs expanded use of J&J's CAR-T therapy https://t.co/6ym07yYs2B https://t.co/af4Jij0t0f
Another win for CAR T - #FDA approval for #Breyanzi in CLL and SLL, a win for patients https://t.co/GOpZVBRibC https://t.co/24gPHtcQvU
Bristol Myers cell therapy wins first-of-its-kind approval https://t.co/Ud8y4myfes vby @realJacobBell $BMY $ALLO
CAR-T treatments have shown promise in the way they can reprogram a patient's immune cells to attack cancer cells but are pricey and have been flagged before for safety concerns. https://t.co/bwsmJUfB6d
While CAR-T treatments from Bristol Myers Squibb's Celgene Corp. and J&J's Janssen Biotech each improved progression-free survival in myeloma trials, FDA in briefing documents flagged concerns about an increased risk of early death from adverse events. https://t.co/F7spdVDSVb
Safety risks hang over CAR-T therapies for myeloma https://t.co/heTqeDIgTo @TreedinDC
Bristol Myers won accelerated approval for the first CAR-T therapy for adults with two forms of hard-to-treat leukemia or lymphoma https://t.co/kGBIwb1rqd